id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12675 R47895 |
Mari (Carbamazepine), 2022 | Gestational diabetes | throughout pregnancy | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 0.11 [0.00;2.96] C | 0/29 1/11 | 1 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8082 R24684 |
Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 | Gestational diabetes mellitus | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.44 [0.05;40.54] C excluded (control group) |
1/15 0/7 | 1 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8074 R24632 |
Aydin (Carbamazepine) (Controls unexposed, sick), 2020 | Gestational diabetes mellitus | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 1.50 [0.09;26.01] C | 1/15 1/22 | 2 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5511 R17488 |
Pennell (Carbamazepine), 2012 | Gestational Diabetes | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.20 [0.02;1.76] C | 1/92 5/97 | 6 | 92 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6424 R17670 |
McVearry (Carbamazepine), 2009 | Gestational diabetes | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.13 [0.07;19.74] C | 1/16 1/18 | 2 | 16 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 0.42 [0.11;1.61] | 11 | 152 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine; 4: Carbamazepine;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 8082